Related Experiment Video

Updated: Jul 11, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Glycogen synthase kinase-3ß inhibitor use and prostate cancer incidence in Manitoba, Canada: A population-based

Christiaan H Righolt1, Emrah Sever2, Salaheddin M Mahmud1

  • 1Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, S108-750 Bannatyne Avenue, Winnipeg, MB R3E 0W2, Canada; College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB R3E 0T5, Canada.

Cancer Epidemiology
|January 15, 2025
PubMed
Abstract

Insights

Glycogen synthase kinase-3ß inhibitors (GSK3Is) showed a potential reduced risk of prostate cancer (PC) in a Manitoba study. However, findings for specific drugs like olanzapine and famotidine require further investigation due to potential confounding factors.

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Limited understanding of glycogen synthase kinase-3ß inhibitors (GSK3Is) class effects on prostate cancer (PC).
  • Previous studies reported mixed results regarding valproate's impact on PC.
  • Need for comprehensive analysis in a defined population.

Purpose of the Study:

  • To investigate the association between GSK3I use and prostate cancer risk.
  • To analyze the effects of specific GSK3Is (lithium, valproate, olanzapine, famotidine) on PC.
  • To examine these associations in relation to bipolar disorder and epilepsy indications.

Main Methods:

  • Nested case-control study in Manitoba, Canada (2000-2018).
  • Matched 11,189 PC patients with 55,728 cancer-free controls based on age, period, and drug data.
  • Conditional logistic regression used to analyze GSK3I use, including dose and duration.

Main Results:

  • Overall GSK3I use was associated with a reduced PC risk (OR=0.81).
  • Famotidine (OR=0.87) and olanzapine (OR=0.72) showed a potential protective effect.
  • Valproate showed a possible protective effect in epilepsy patients (OR=0.35), but not in bipolar disorder patients.

Conclusions:

  • The potential PC protective effects of olanzapine and famotidine lack dose-response evidence, suggesting possible chance or confounding.
  • Valproate's association with lower PC risk in epilepsy patients needs larger studies for confirmation.
  • Further research is required to clarify GSK3Is' role in prostate cancer prevention.
Keywords:
Cancer chemopreventionFamotidineLithiumOlanzapineValproate (valproic acid)

More Related Videos

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation09:23

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation

Published on: August 18, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165